Abstract
We report on the effects and complications associated with low dose sequential methotrexate (MTX) and 5-fluorouracil (5-FU) (MF therapy) as neo-adjuvant chemotherapy in oral cancer. The oral cancer of 19 patients was treated as follows: MTX (75 mg/body) was administered by intravenous infusion for 1 hour, followed by 5-FU (500 mg/body) intravenous infusion for 2 hours, on Day 1, MTX (75 mg/body) intravenous infusion for 1 hour on Day 4, and parenteral dose of leucovorin on Day 2 and Day 5. A complete response was attained in one patient and a partial response in 11 patients. Complications observed were: increased serum transaminase levels (4), leucopenia (3), nausea or vomiting (4), anemia (1). The MF therapy of 2-8 courses was performed weekly or every 2 weeks. The volume in tumors of all cases decreased. Toxicity was extremely mild and radiotherapy or operation could be added sequentially without increased toxicity. These results suggests that MF therapy is effective and safety as neo-adjuvant chemotherapy before radiation and surgery for patients in oral cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 559-562 |
| Number of pages | 4 |
| Journal | In Vivo |
| Volume | 10 |
| Issue number | 6 |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- Low dose
- Neo-adjuvant chemotherapy
- Oral cancer
- Sequential methotrexate and 5-fluorouracil
ASJC Scopus subject areas
- Medicine(all)
Cite this
Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer. / Asaumi, Jun-Ichi; Nishijima, Katsumi.
In: In Vivo, Vol. 10, No. 6, 1996, p. 559-562.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer
AU - Asaumi, Jun-Ichi
AU - Nishijima, Katsumi
PY - 1996
Y1 - 1996
N2 - We report on the effects and complications associated with low dose sequential methotrexate (MTX) and 5-fluorouracil (5-FU) (MF therapy) as neo-adjuvant chemotherapy in oral cancer. The oral cancer of 19 patients was treated as follows: MTX (75 mg/body) was administered by intravenous infusion for 1 hour, followed by 5-FU (500 mg/body) intravenous infusion for 2 hours, on Day 1, MTX (75 mg/body) intravenous infusion for 1 hour on Day 4, and parenteral dose of leucovorin on Day 2 and Day 5. A complete response was attained in one patient and a partial response in 11 patients. Complications observed were: increased serum transaminase levels (4), leucopenia (3), nausea or vomiting (4), anemia (1). The MF therapy of 2-8 courses was performed weekly or every 2 weeks. The volume in tumors of all cases decreased. Toxicity was extremely mild and radiotherapy or operation could be added sequentially without increased toxicity. These results suggests that MF therapy is effective and safety as neo-adjuvant chemotherapy before radiation and surgery for patients in oral cancer.
AB - We report on the effects and complications associated with low dose sequential methotrexate (MTX) and 5-fluorouracil (5-FU) (MF therapy) as neo-adjuvant chemotherapy in oral cancer. The oral cancer of 19 patients was treated as follows: MTX (75 mg/body) was administered by intravenous infusion for 1 hour, followed by 5-FU (500 mg/body) intravenous infusion for 2 hours, on Day 1, MTX (75 mg/body) intravenous infusion for 1 hour on Day 4, and parenteral dose of leucovorin on Day 2 and Day 5. A complete response was attained in one patient and a partial response in 11 patients. Complications observed were: increased serum transaminase levels (4), leucopenia (3), nausea or vomiting (4), anemia (1). The MF therapy of 2-8 courses was performed weekly or every 2 weeks. The volume in tumors of all cases decreased. Toxicity was extremely mild and radiotherapy or operation could be added sequentially without increased toxicity. These results suggests that MF therapy is effective and safety as neo-adjuvant chemotherapy before radiation and surgery for patients in oral cancer.
KW - Low dose
KW - Neo-adjuvant chemotherapy
KW - Oral cancer
KW - Sequential methotrexate and 5-fluorouracil
UR - http://www.scopus.com/inward/record.url?scp=0030481578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030481578&partnerID=8YFLogxK
M3 - Article
VL - 10
SP - 559
EP - 562
JO - In Vivo
JF - In Vivo
SN - 0258-851X
IS - 6
ER -